Feds Halt Production at Emergent BioSolution's COVID-19 Vaccine Plant in Baltimore
Feds Halt Production at Emergent BioSolution's COVID-19 Vaccine Plant in Baltimore
SUGAR LAND--April 23, 2021--Researched by Industrial Info Resources (Sugar Land, Texas)--Armed with a list of manufacturing violations, the Food and Drug Administration (FDA) has halted production at contract manufacturer (CMO) Emergent BioSolution's Bayview plant in Baltimore, Maryland. In addition, 60 million doses of the Johnson & Johnson (NYSE:JNJ) "one-shot" COVID-19 vaccines have been quarantined, meaning the bulk drug product will not be shipped to a fill-and-finish facility for completion.
Companies featured: Johnson & Johnson (NYSE:JNJ)
Subscribe Now!(All Fields Required)
Related Articles
Articles related to this company
- Samsung Biologics Constructing ADC Plant in South Korea
- Data Center Activity Propels Virginia to $12.7 Billion of Projects Under Co...
- Pharma Company Zoetis Signs PPA with Scout Clean Energy to Support Growing ...
- China's Rongsheng Petrochemical Ups Role in Polyester Chips
- Suffolk Construction Has Hand in $1.9 Billion Worth of Projects